RLMD Key Statistics, Chart & Performance
The current stock price of RLMD is 4.24 USD. In the past month the price increased by 62.45%. In the past year, price increased by 826.78%.
RLMD Latest News, Press Relases and Analysis
RLMD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.94 | 955.13B | ||
| JNJ | JOHNSON & JOHNSON | 19.45 | 486.51B | ||
| MRK | MERCK & CO. INC. | 11.32 | 247.51B | ||
| PFE | PFIZER INC | 8.13 | 148.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.95 | 106.16B | ||
| ZTS | ZOETIS INC | 18.71 | 52.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 22.93B | ||
| VTRS | VIATRIS INC | 4.69 | 12.59B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.81 | 10.88B | ||
| CORT | CORCEPT THERAPEUTICS INC | 97.85 | 9.06B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.52B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.23B |
Related stock screener links
About RLMD
Company Profile
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. The company is headquartered in Coral Gables, Florida and currently employs 17 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Company Info
RELMADA THERAPEUTICS INC
2222 Ponce De Leon Blvd. 3Rd Floor
Coral Gables FLORIDA 10022 US
CEO: Sergio Traversa
Employees: 17
Phone: 16468763459
RELMADA THERAPEUTICS INC / RLMD FAQ
What does RELMADA THERAPEUTICS INC do?
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. The company is headquartered in Coral Gables, Florida and currently employs 17 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
What is the stock price of RELMADA THERAPEUTICS INC today?
The current stock price of RLMD is 4.24 USD. The price increased by 6% in the last trading session.
Does RELMADA THERAPEUTICS INC pay dividends?
RLMD does not pay a dividend.
What is the ChartMill technical and fundamental rating of RLMD stock?
RLMD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy RLMD stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RLMD.
What is the market capitalization of RLMD stock?
RELMADA THERAPEUTICS INC (RLMD) has a market capitalization of 310.92M USD. This makes RLMD a Small Cap stock.
Can you provide the ownership details for RLMD stock?
You can find the ownership structure of RELMADA THERAPEUTICS INC (RLMD) on the Ownership tab.
RLMD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RLMD. When comparing the yearly performance of all stocks, RLMD is one of the better performing stocks in the market, outperforming 99.72% of all stocks.
RLMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RLMD. The financial health of RLMD is average, but there are quite some concerns on its profitability.
RLMD Financial Highlights
Over the last trailing twelve months RLMD reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS increased by 37.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -377.61% | ||
| ROE | -593.47% | ||
| Debt/Equity | 0 |
RLMD Forecast & Estimates
8 analysts have analysed RLMD and the average price target is 10.2 USD. This implies a price increase of 140.57% is expected in the next year compared to the current price of 4.24.